BACKGROUND/AIMS: Human papilloma virus (HPV) infection in esophageal cancer cases has been found in 0-70%, depending on different methods and geographical variances. Complete pathological response has been found in 30% of cases after neoadjuvant chemo-radiation (CRX). The aim of this study was to discover a possible relation between HPV-infection and response. METHODOLOGY: DNA was obtained from 26 esophageal cancer patients undergoing CRX and surgery. Polymerase chain reaction (PCR) and Southern Blot hybridization was used to detect HPV-infection (HPV-16 and -18). Clinicopathological parameters, disease-free survival and overall survival were also analyzed. RESULTS: Complete response (26.9%) and partial response (38.5%) after CRX was correlated significantly with better prognosis. Six patients had HPV-infection (3 from the CR- and 3 from PR-group). CONCLUSIONS: There was correlation between HPV-infection and response, but further analyses are necessary. Both responder-groups had a significantly better prognosis than non-responders.
BACKGROUND/AIMS: Human papilloma virus (HPV) infection in esophageal cancer cases has been found in 0-70%, depending on different methods and geographical variances. Complete pathological response has been found in 30% of cases after neoadjuvant chemo-radiation (CRX). The aim of this study was to discover a possible relation between HPV-infection and response. METHODOLOGY: DNA was obtained from 26 esophageal cancerpatients undergoing CRX and surgery. Polymerase chain reaction (PCR) and Southern Blot hybridization was used to detect HPV-infection (HPV-16 and -18). Clinicopathological parameters, disease-free survival and overall survival were also analyzed. RESULTS: Complete response (26.9%) and partial response (38.5%) after CRX was correlated significantly with better prognosis. Six patients had HPV-infection (3 from the CR- and 3 from PR-group). CONCLUSIONS: There was correlation between HPV-infection and response, but further analyses are necessary. Both responder-groups had a significantly better prognosis than non-responders.
Authors: Ioannis N Mammas; George Sourvinos; Apostolos Zaravinos; Demetrios A Spandidos Journal: Pathol Oncol Res Date: 2010-07-18 Impact factor: 3.201
Authors: Laura Bognár; Ivett Hegedűs; Szabolcs Bellyei; Éva Pozsgai; László Zoltán; Katalin Gombos; Örs Péter Horváth; András Vereczkei; András Papp Journal: Infect Agent Cancer Date: 2018-11-29 Impact factor: 2.965
Authors: Hedvig E Löfdahl; Juan Du; Anders Näsman; Emilia Andersson; Carlos A Rubio; Yunxia Lu; Torbjörn Ramqvist; Tina Dalianis; Jesper Lagergren; Hanna Dahlstrand Journal: PLoS One Date: 2012-10-12 Impact factor: 3.240